Chemotherapy Induced Pain Market

Key Highlights

• As per Burgess et al. (2021), the prevalence of Chemotherapy-Induced Peripheral Neuropathy one month after finishing chemotherapy approaches 68%, and persists in approximately one third of patients beyond 6 months.

• According to Coffeen et al. (2019), Chemotherapy-Induced Peripheral Neuropathy is present in up to 68.1% of the patients within 1 month of receiving Chemotherapy and about 30% may still be presenting symptoms 6 months after treatment discontinuation.

• Chemotherapy-Induced Pain epidemiology is segmented as Total Chemotherapy-Induced Pain Incident Cases, Chemotherapy-Induced Pain Diagnosed and Treatable Cases and Total Chemotherapy-Induced Pain Prevalence based on Duration Post-Chemotherapy in the Chemotherapy-Induced Pain Market Report.

Request for unlock CAGR of Chemotherapy-Induced Pain Market

DelveInsight's "Chemotherapy-Induced Pain Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Chemotherapy-Induced Pain, historical and forecasted epidemiology as well as the Chemotherapy-Induced Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chemotherapy-Induced Pain market report provides current treatment practices, emerging drugs, Chemotherapy-Induced Pain market share of the individual therapies, current and forecasted Chemotherapy-Induced Pain market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Chemotherapy-Induced Pain treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032

Chemotherapy-Induced Pain Market Disease Understanding and Treatment Algorithm

The DelveInsight’s Chemotherapy-Induced Pain market report gives a thorough understanding of Chemotherapy-Induced Pain by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Chemotherapy-induced peripheral neuropathy is a disabling pain condition resulting from chemotherapy for cancer. Peripheral neuropathy usually manifests as painful symptoms, characterizing a neuropathic pain syndrome. Moreover, observed symptoms vary in intensity and duration and range from acute, transient thermal sensations to permanent changes in peripheral nerves accompanied by chronic pain and irreversible nerve damage.

The symptoms range from early post-treatment pain, such as the paclitaxel acute pain syndrome (P-APS), to paraesthesias, sensory ataxia, and mechanical and cold allodynia. The extremities of the body are predominantly affected, but the pain can proceed along the limbs during repetitive treatment. Substances that cause Chemotherapy-induced peripheral neuropathy pain include the commonly used taxanes, platinum derivatives and vinca alkaloids, as well as the more rarely used ixabepilone, bortezomib and thalidomide. In addition chemotherapy-induced pain and sensory abnormalities may persist for months or even years after the cessation of chemotherapy. Moreover, painful sensations, including spontaneous burning, shooting or electric shock-like pain as well as mechanical or thermal allodynia or hyperalgesia frequently occur.

Chemotherapy-Induced Pain Diagnosis

Electrodiagnostic methods are considered the reference standard for the functional assessment of large sensory and motor fibers which drive paraesthesia, numbness and weakness seen in people with Chemotherapy-Induced Pain. Although sensory testing used in composite scoring systems is often deployed in the Chemotherapy-Induced Pain clinical trial setting, a rigorous, lengthy battery of standardized sensory tests is required to reliably identify a patient’s sensory phenotype.

Chemotherapy-Induced Pain Treatment

Several classes of drugs already known to be effective in the neuropathic pain control, such as antidepressants and anticonvulsants. In addition, non-steroidal anti-inflammatory drugs (NSAIDs) that can reduce pain symptoms and the underlying inflammation associated with pain are used. Moreover Opioids and other painkillers may also be used in cases of severe pain. Currently, duloxetine is the only agent endorsed by the American society of clinical oncology and ESMO guidelines for treatment for Chemotherapy-induced peripheral neuropathy.

Painful Chemotherapy-induced peripheral neuropathy remains under recognized and undertreated. It is an important cause of pain during cancer treatment and is a common pain in the cancer survivor. However, difficulties in assessment and limitations in treatment contribute to management problems.

Chemotherapy-Induced Pain Epidemiology

The Chemotherapy-Induced Pain epidemiology section provides insights about historical and current Chemotherapy-Induced Pain patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Learn more about the evolving epidemiology trends and key developments: Chemotherapy-Induced Pain Epidemiology Forecast
 

Key Findings

• As per Burgess et al. (2021), the prevalence of Chemotherapy-Induced Peripheral Neuropathy one month after finishing chemotherapy approaches 68%, and persists in approximately one third of patients beyond 6 months.

• According to Coffeen et al. (2019), Chemotherapy-Induced Peripheral Neuropathy is present in up to 68.1% of the patients within 1 month of receiving Chemotherapy and about 30% may still be presenting symptoms 6 months after treatment discontinuation.

• The disease epidemiology covered in the report provides historical as well as forecasted Chemotherapy-Induced Pain epidemiology [segmented as Total Incident Cases of Chemotherapy-Induced Pain, Diagnosed and Treatable Cases of Chemotherapy-Induced Neuropathic Pain, and Total Prevalence of Chemotherapy-Induced Neuropathic Pain based on Duration Post-Chemotherapy] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Chemotherapy-Induced Pain Epidemiology

This section provides glimpse of the Chemotherapy-Induced Pain epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Chemotherapy-Induced Pain Drug Chapters

The drug chapter segment of the Chemotherapy-Induced Pain report encloses the detailed analysis of Chemotherapy-Induced Pain marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Chemotherapy-Induced Pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Chemotherapy-Induced Pain Marketed Drugs

Note: Detailed Current therapies assessment will be provided in the full report of Chemotherapy-Induced Pain

Chemotherapy-Induced Pain Emerging Drugs

Halneuron is WEX Pharmaceuticals’s primary product that is currently under development. Halneuron’s active pharmaceutical ingredient is Tetrodotoxin (“TTX”), a small molecule known to block voltage-gated sodium channels on neurons and prevents pain by inhibiting the initiation and conduction of nerve impulses in the peripheral nervous system which is associated with pain. Halneuron is administered by subcutaneous injection.

Note: Detailed emerging therapies assessment will be provided in the full report of Chemotherapy-Induced Pain

Chemotherapy-Induced Pain Market Outlook

Several compounds have been investigated in clinical studies for their efficiency in prevention of Chemotherapy-Induced Pain, including anticonvulsants, antidepressants, vitamins, minerals, and other chemoprotectants without reliable or conclusive clinically meaningful benefits. Hence, there is no strong evidence for an established or recommended medical prophylaxis of Chemotherapy-Induced Pain. Recommendations in current guidelines are mainly based on low-quality medical evidence.

The first line of treatments for Chemotherapy-Induced Pain include the serotonin noradrenaline reuptake inhibitors (SNRIs) duloxetine. The second line of treatments include 5% lidocaine patches, 8%capsaicin patches and weak opioids, primarily tramadol. The third line of treatment is strong opioids, which carry a high potential for side effects, addiction, and dependence. Non-opioid analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs), metamizole, or paracetamol may be effective in reducing swelling and corresponding pain caused by tissue swelling due to chronic venous insufficiency.

The available pharmacotherapies for CINP and associated pain are poorly effective and associated with numerous side-effects. However, the search for more effective treatments is difficult as the physiopathology of CINP involves a complex machinery Therefore, a deep knowledge of the molecular mechanisms involved in CINP is crucial to provide new molecular mechanism-based therapies instead of simply treating symptoms.

The unmet needs in management of Chemotherapy-Induced Pain and associated pain is the inadequate diagnosis and a lack of appreciation of the mechanisms involved; insufficient management of comorbid conditions; incorrect selection of treatment options; and the use of inappropriate outcomes measures.

The dynamics of Chemotherapy-Induced Pain market is anticipated to change in the coming years owing to the improvement in the research and development undertaking, leading to development of new therapies. Key players such as WEX Pharmaceuticals and others are involved in developing therapies for Chemotherapy-Induced Pain.

According to DelveInsight, Chemotherapy-Induced Pain market in 7MM is expected to witness a major change in the study period 2019-2032.

Analyst Commentary

• The pipeline of Chemotherapy-Induced Pain is very robust, many potential therapies are being investigated for the treatment of Chemotherapy-Induced Pain, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Chemotherapy-Induced Pain market in the 7MM. Aside from that, the market size of Chemotherapy-Induced Pain may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

• The market growth of Chemotherapy-Induced Pain may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Chemotherapy-Induced Pain Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Chemotherapy-Induced Pain market or expected to get launched in the market during the study period 2019-2032. The analysis covers Chemotherapy-Induced Pain market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in full report of Chemotherapy-Induced Pain.

Chemotherapy-Induced Pain Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Chemotherapy-Induced Pain key players involved in developing targeted therapeutics.

Chemotherapy-Induced Pain Clinical Trial Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Chemotherapy-Induced Pain emerging therapies.

Reimbursement Scenario in Chemotherapy-Induced Pain

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Chemotherapy-Induced Pain domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chemotherapy-Induced Pain market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Chemotherapy-Induced Pain Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Chemotherapy-Induced Pain Market Report

• The report covers the descriptive overview of Chemotherapy-Induced Pain, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Chemotherapy-Induced Pain epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Chemotherapy-Induced Pain are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Chemotherapy-Induced Pain market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the Global Chemotherapy-Induced Pain market

Chemotherapy-Induced Pain Market Report Highlights

• In the coming years, the Chemotherapy-Induced Pain market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy-Induced Pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• Major players are involved in developing therapies for Chemotherapy-Induced Pain. The launch of emerging therapies will significantly impact the Chemotherapy-Induced Pain market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chemotherapy-Induced Pain
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Chemotherapy-Induced Pain clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chemotherapy-Induced Pain Report Insights

• Patient Based Market Forecasting
• Therapeutic Approaches
• Chemotherapy-Induced Pain Pipeline Analysis
• Chemotherapy-Induced Pain Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Chemotherapy-Induced Pain Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Chemotherapy-Induced Pain Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Chemotherapy-Induced Pain Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the Chemotherapy-Induced Pain drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Chemotherapy-Induced Pain total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Chemotherapy-Induced Pain market size during the forecast period (2019-2032)?
• At what CAGR, the Chemotherapy-Induced Pain market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Chemotherapy-Induced Pain market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Chemotherapy-Induced Pain market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Chemotherapy-Induced Pain?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Chemotherapy-Induced Pain patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Chemotherapy-Induced Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Chemotherapy-Induced Pain?
• Out of all 7MM countries, which country would have the highest prevalent population of Chemotherapy-Induced Pain during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Chemotherapy-Induced Pain treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Chemotherapy-Induced Pain in the USA, Europe, and Japan?
• What are the Chemotherapy-Induced Pain marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Chemotherapy-Induced Pain?
• How many therapies are in-development by each company for Chemotherapy-Induced Pain treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Chemotherapy-Induced Pain treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy-Induced Pain therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chemotherapy-Induced Pain and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Chemotherapy-Induced Pain?
• What are the global historical and forecasted markets of Chemotherapy-Induced Pain?

Reasons to buy

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Chemotherapy-Induced Pain market
• Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy-Induced Pain in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Chemotherapy-Induced Pain market
• To understand the future market competition in the Chemotherapy-Induced Pain market